Atopic Dermatitis
Patients with unresponsive atopic dermatitis saw improvement with rocatinlimab
ORLANDO — Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab compared with placebo, according to a presenter at the American Academy of Dermatology Annual Meeting
Diet represents ‘one piece of the puzzle’ in managing atopic dermatitis
ORLANDO — Nutrition plays a role in the management of atopic dermatitis, according to research presented at the American Academy of Dermatology Annual Meeting.
Dupilumab improves lichenification in atopic dermatitis across age, racial groups
Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive scratching, among patients of varying ages and races with atopic dermatitis, according to a study.
Allergists prefer second- vs. first-generation antihistamines, but some prefer both
SAN DIEGO — Across six different situations, more allergists preferred second- vs. first-generation antihistamines; however, in five situations, at least 18% reported preference for both antihistamines, according to a poster presented here.
‘Will make life better’: FDA advances Zoryve cream 0.05% for pediatric atopic dermatitis
The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years, according to a press release from the manufacturer.
Dupilumab linked to reduced risks for psychiatric disorders in atopic dermatitis
Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments, according to a study published in Annals of Allergy, Asthma & Immunology.
FDA clears investigational new drug application for Zabalafin Hydrogel
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has been cleared by the FDA, Alphyn Biologics announced in a press release.
Connection between skin disease, heart health ushers in ‘holistic’ era of dermatology
In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.
Nemluvio approved in EU, UK, Switzerland for atopic dermatitis, prurigo nodularis
Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo nodularis in the European Union, Galderma announced in a press release.
Rezpegaldesleukin gets FDA fast track designation for atopic dermatitis
The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate to severe atopic dermatitis that topical therapies have not adequately controlled, according to a press release.